Last reviewed · How we verify

NCT04282057

Effects of Shockwave Therapy Versus Radiofrequency

Completed NA Last updated 30 September 2020
What this trial tests

NA trial testing Radiofrequency in Cardiovascular Risk Factor in 30 participants. Completed in 19 June 2020.

Timeline
22 February 2020
Primary endpoint
25 April 2020
19 June 2020

Quick facts

Lead sponsorEscola Superior de Tecnologia da Saúde do Porto
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment30
Start date22 February 2020
Primary completion25 April 2020
Estimated completion19 June 2020
Sites1 location across Portugal

Drugs / interventions tested

Conditions studied

Sponsor

Escola Superior de Tecnologia da Saúde do Porto

Who can join

Adults 18 to 60, female only, with Cardiovascular Risk Factor or Metabolic Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of this study is to compare the effect of 6 sessions of shock wave therapy versus radiofrequency followed by a protocol of moderate aerobic exercise, in the reduction of adiposity and abdominal flaccidity, in females between 18 and 60 years old. As a secondary objective, it is intended to understand the mechanism of fat mobilization by these two therapies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Radiofrequency

Trials testing the same drug.

Other recruiting trials for Cardiovascular Risk Factor

Currently open trials in the same condition.

Other Escola Superior de Tecnologia da Saúde do Porto trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04282057.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing